Amicus Therapeutics, a biopharmaceutical company focused on the development of oral therapeutics for the treatment of genetic diseases, has announced the election of Sol Barer to its board of directors. Barer is currently chairman and CEO of Celgene Corporation.
Achillion Pharmaceuticals, a developer of small molecule drugs for the treatment of infectious diseases, has announced the appointment of Joseph Truitt as vice president of business development and chief commercial officer. Truitt will be responsible for identifying, evaluating and executing corporate partnerships, strategic initiatives and new product opportunities.
Auspex Pharmaceuticals, a clinical stage developer of next-generation medicines with improved safety and performance, announced the appointment of Michael Grey as president and CEO, and Gary Gilmore as chief financial officer. Grey was previously CEO of SGX Pharmaceuticals, which was recently acquired by Eli Lilly. Grey was formerly president and CEO of Trega Biosciences, which was acquired by LION bioscience, AG.